


## JBJ-02-112-05

Cat. No.:	HY-135914
CAS No.:	2748162-29-8
Molecular Formula:	C <sub>27</sub> H <sub>20</sub> N <sub>4</sub> O <sub>2</sub> S
Molecular Weight:	464.54
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC <sub>50</sub> of 15 nM for EGFR L858R/T790M <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	EGFR <sup>L858R/T790M</sup> 15 nM (IC <sub>50</sub> )
<b>In Vitro</b>	In Ba/F3 cells, JBJ-02-112-05 inhibits the activities of wildtype EGFR, EGFR <sup>L858R</sup> , EGFR <sup>L858R/T790M</sup> and EGFR <sup>L858R/T790M/C797S</sup> with IC <sub>50</sub> values of 9.29 μM; 8.35 μM; 8.53 μM and 2.13 μM, respectively <sup>[1]</sup> . JBJ-02-112-05 demonstrates mutant selectivity by inhibiting mutant EGFR and downstream AKT and ERK1/2 phosphorylation in Ba/F3 cells stably transfected with EGFR <sup>L858R</sup> , EGFR <sup>L858R/T790M</sup> , EGFR <sup>L858R/T790M/C797S</sup> mutations <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	JBJ-02-112-05 (100 mg/kg; oral gavage; once daily; for 3 days; EGFR <sup>L858R/T790M/C797S</sup> genetically engineered mice) treatment inhibits phosphorylation of EGFR and downstream signaling pathways <sup>[1]</sup> . JBJ-02-112-05 exhibits a moderate half-life of 3 hours and a C <sub>max</sub> of 13.7 μM following 3 mg/kg intravenous (i.v.) dose. A 5 mg/kg oral dose of JBJ-02-112-05 achieves a half-life of 16.4 hours and a C <sub>max</sub> of 1.31 μM <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	EGFR <sup>L858R/T790M/C797S</sup> genetically engineered mice <sup>[1]</sup>
Dosage:	100 mg/kg
Administration:	Oral gavage; once daily; for 3 days
Result:	Inhibited phosphorylation of EGFR and downstream signaling pathways.

### REFERENCES

[1]. To C, et al. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. *Cancer Discov.* 2019 Jul;9(7):926-943.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA